CCCC - C4 Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Watertown,
United States
Type: Equity
CCCC price evolution
CCCC
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $76.56 | $93.1 | $130.03 | |
| Short term investments | $190.98 | $168.53 | $127.09 | |
| Net receivables | $10.34 | $1.17 | $13.6 | $11.8 |
| Inventory | ||||
| Total current assets | $273.23 | $276.04 | $279.59 | $271.19 |
| Long term investments | $31.64 | $40.98 | $28.01 | |
| Property, plant & equipment | $65.37 | $67.35 | $69.13 | $71.09 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $105.05 | $118.78 | $105.26 | |
| Total investments | $222.62 | $209.51 | $155.1 | |
| Total assets | $376.06 | $381.09 | $398.37 | $376.45 |
| Current liabilities | ||||
| Accounts payable | $1.5 | $0.91 | $1.63 | $1.45 |
| Deferred revenue | $53.5 | $55.85 | $37.28 | |
| Short long term debt | $5.49 | $5.36 | $5.22 | |
| Total current liabilities | $43.29 | $54.2 | $55.02 | $42.77 |
| Long term debt | $62.92 | $64.36 | $65.76 | |
| Total noncurrent liabilities | $79.83 | $85.07 | $87.57 | |
| Total debt | $68.42 | $69.72 | $70.98 | |
| Total liabilities | $133.4 | $134.03 | $140.09 | $130.34 |
| Shareholders' equity | ||||
| Retained earnings | -$599.13 | -$574.46 | -$556.74 | -$528.38 |
| Other shareholder equity | $0.46 | -$0.44 | -$0.38 | -$0.13 |
| Total shareholder equity | $247.06 | $258.28 | $246.11 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $130.03 | $33.03 | $79.4 | $184.3 |
| Short term investments | $127.09 | $246.4 | $233.16 | $189.96 |
| Net receivables | $11.8 | $1.47 | $5.72 | $4.48 |
| Inventory | ||||
| Total current assets | $271.19 | $287.56 | $325.69 | $381.01 |
| Long term investments | $28.01 | $60.96 | $142.2 | |
| Property, plant & equipment | $71.09 | $77.52 | $35.05 | $16.55 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $105.26 | $143.28 | $181.08 | $19.13 |
| Total investments | $155.1 | $307.36 | $375.36 | $189.96 |
| Total assets | $376.45 | $430.84 | $506.76 | $400.14 |
| Current liabilities | ||||
| Accounts payable | $1.45 | $1.17 | $4.51 | $5.68 |
| Deferred revenue | $37.28 | $33.51 | $56.17 | $81.22 |
| Short long term debt | $5.22 | $6.99 | $1.33 | $1.04 |
| Total current liabilities | $42.77 | $44.55 | $51.25 | $43.85 |
| Long term debt | $65.76 | $9.2 | $41.55 | $21.88 |
| Total noncurrent liabilities | $87.57 | $97.06 | $65.91 | $75.5 |
| Total debt | $70.98 | $87.15 | $42.88 | $22.92 |
| Total liabilities | $130.34 | $141.61 | $117.16 | $119.35 |
| Shareholders' equity | ||||
| Retained earnings | -$528.38 | -$395.89 | -$267.71 | -$183.82 |
| Other shareholder equity | -$0.13 | -$4.14 | -$0.78 | $0.01 |
| Total shareholder equity | $246.11 | $289.23 | $389.61 | $280.79 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15.36 | $12.01 | $3.04 | $3.26 |
| Cost of revenue | ||||
| Gross Profit | $12.01 | $3.04 | $3.26 | |
| Operating activities | ||||
| Research & development | $23.75 | $22.53 | $30.39 | |
| Selling, general & administrative | $9.7 | $10.29 | $10.3 | |
| Total operating expenses | $43.61 | $33.45 | $35.26 | $40.69 |
| Operating income | -$21.44 | -$32.22 | -$37.43 | |
| Income from continuing operations | ||||
| EBIT | -$17.72 | -$28.36 | -$34.48 | |
| Income tax expense | $0.28 | |||
| Interest expense | $3.58 | |||
| Net income | ||||
| Net income | -$24.67 | -$17.72 | -$28.36 | -$34.75 |
| Income (for common shares) | -$17.72 | -$28.36 | -$34.75 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $20.76 | $31.1 | $45.78 | $33.2 |
| Cost of revenue | ||||
| Gross Profit | $20.76 | $31.1 | $45.78 | $33.2 |
| Operating activities | ||||
| Research & development | $117.71 | $117.84 | $94.67 | $78.44 |
| Selling, general & administrative | $42.08 | $42.79 | $33.25 | $15.2 |
| Total operating expenses | $159.79 | $160.63 | $127.92 | $93.64 |
| Operating income | -$139.03 | -$129.53 | -$82.13 | -$60.45 |
| Income from continuing operations | ||||
| EBIT | -$129.84 | -$125.96 | -$81.75 | -$65.73 |
| Income tax expense | $1.28 | -$0.63 | ||
| Interest expense | $1.37 | $2.22 | $2.15 | $1.23 |
| Net income | ||||
| Net income | -$132.49 | -$128.18 | -$83.89 | -$66.33 |
| Income (for common shares) | -$132.49 | -$128.18 | -$83.89 | -$66.33 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$17.72 | -$28.36 | -$34.75 | |
| Operating activities | ||||
| Depreciation | $2.04 | $2.03 | $1.99 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.38 | $6.21 | $6.36 | |
| Total cash flows from operations | -$4.97 | -$18.12 | -$24.01 | |
| Investing activities | ||||
| Capital expenditures | -$0.2 | -$0.16 | ||
| Investments | -$11.51 | -$53.4 | $32.1 | |
| Total cash flows from investing | -$64.94 | -$11.71 | -$53.4 | $31.95 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.14 | $14.5 | $57.67 | |
| Net borrowings | ||||
| Total cash flows from financing | $45.22 | $0.14 | $34.58 | $57.67 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$66.94 | -$16.55 | -$36.93 | $65.61 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$132.49 | -$128.18 | -$83.89 | -$66.33 |
| Operating activities | ||||
| Depreciation | $8.04 | $7.57 | $1.49 | $2.84 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $27.23 | $30.02 | $21.51 | $3.43 |
| Total cash flows from operations | -$106.84 | -$105.94 | -$86.97 | -$67.25 |
| Investing activities | ||||
| Capital expenditures | -$1.71 | -$5.5 | -$1.28 | -$0.65 |
| Investments | $160.06 | $63.92 | -$188.06 | -$189.85 |
| Total cash flows from investing | $158.35 | $58.42 | -$189.34 | -$190.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $57.62 | $0.78 | $171.51 | $192.16 |
| Net borrowings | -$12.5 | $11.97 | ||
| Total cash flows from financing | $45.49 | $1.15 | $171.4 | $348.93 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $97 | -$46.37 | -$104.9 | $91.18 |
News
Fundamentals
| Market cap | $240.62M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 70.56M |
| Revenue | $33.67M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$105.50M |
| Revenue Q/Q | 38.75% |
| Revenue Y/Y | 65.45% |
| P/E ratio | -2.28 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 7.15 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.50 |
|---|---|
| ROA | -27.55% |
| ROE | N/A |
| Debt/Equity | 0.53 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.31 |
| Quick ratio | N/A |